TONIX PHARMACEUTICALS HOLDING CORP.

Drug pipeline (5)

Asset	Stage	Revenue	Trials	Status
TONMYA	approved	$11.0MQ2 2026	0	—
ZEMBRACE SYMTOUCH	approved	$2.0MQ2 2026	7	approved
TOSYMRA	approved	$0.6MQ2 2026	8	approved
DEXISOMETHEPTENE MUCATE	phase2	—	2	no active trials
OXYTOCIN	phase2	—	1	no active trials

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (34)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02015234	phase3	completed	2013-12-01	2015-08-01	Tonix Pharmaceuticals, Inc.	12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT03110575	phase3	terminated	2017-06-20	2018-07-27	Tonix Pharmaceuticals, Inc.	12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
NCT02589275	phase3	completed	2015-08-04	2016-09-28	Tonix Pharmaceuticals, Inc.	A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT03508700	phase3	completed	2018-04-19	2019-09-30	Tonix Pharmaceuticals, Inc.	A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
NCT01490788	phase1	completed	2011-11-18	2011-12-30	Tonix Pharmaceuticals, Inc.	A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

FDA applications (3)

Application

Approved

Type

Applicant

Products

NDA 219428

2025-08-15

NDA

TONIX PHARMACEUTICALS INC

NDA 210884

2019-01-25

NDA

TONIX MEDICINES INC

NDA 208223

2016-01-28

NDA

TONIX MEDICINES INC